Business Context and Reporting Period
This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) for the period ending September 21, 2009, reporting events occurring on September 16, 2009. The filing discloses the consummation of a stock purchase transaction and the unredacted identity of a partner in a prior research agreement.
Key Financial Metrics and Transaction Details
- Transaction Type: Unregistered sale of equity securities and entry into a material definitive agreement.
- Investor: Teva Pharmaceutical Industries Limited.
- Shares Sold: 3,102,837 shares of Common Stock.
- Price Per Share: $1.128.
- Total Consideration Received: $3,500,000.
- Underlying Asset: Development of RX-3117, a nucleoside compound with anti-metabolite mechanism for cancer treatment.
Material Changes and Future Obligations
The primary material change is the disclosure of Teva Pharmaceutical Industries Limited as the counterparty to agreements previously filed with redacted identities. Additionally, the filing outlines future funding options:
- Second Tranche Option: Teva has the option to purchase additional shares valued at $750,000 plus anticipated development costs. The price will be 120% of the closing price prior to purchase, subject to a 7% ownership cap.
- Additional Funding: If further funding is required after the second tranche, Teva may provide it in exchange for shares at 100% of the closing price, also subject to the 7% ownership cap.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance, revenue forecasts, or management commentary on future performance beyond the transaction terms. Key contingencies include:
- The success of the development of the RX-3117 compound.
- Teva's exercise of options to purchase additional shares, which depends on development cost requirements and market prices.
- Compliance with the 7% ownership limitation for future share issuances.
Investor Verification Checklist
- Verify the current status and clinical trial progress of the RX-3117 compound.
- Confirm the total number of outstanding shares to assess the dilution impact of the 3,102,837 shares sold and potential future issuances.
- Review the full text of the Research and Exclusive License Option Agreement (Exhibit 10.1) for confidential terms regarding milestones and royalties.
- Monitor whether Teva exercises the option for the second tranche of funding.